-
How many large pharmaceutical companies’ profit revenues can’t even reach the “good value
Time of Update: 2021-05-10
Starting from Zheng Xiaoyu's large number of drug registrations, many pharmaceutical companies have experienced the days of making money every day by taking advantage of the asymmetry of information.
-
Eli Lilly closes Dermira plant to transfer hyperhidrosis drug Qbrexza
Time of Update: 2021-05-10
CompilationFan DongdongA few days ago, Eli Lilly announced that it would close its Dermira plant in Menlo Park, lay off 163 employees, and intend to sell the hyperhidrosis drug Qbrexza to Journey Medical.
-
How do we choose the anesthesia method for labor analgesia and transfer to cesarean section
Time of Update: 2021-05-10
, and sufficient time to operate; [Advantages] Fast onset, good effect, and precise effect; [Operation suggestion] Choose a puncture below the epidural catheter, optional Local anesthetics include 15-20mg of ropivacaine and 10-12mg of bupivacaine
-
National Food and Drug Administration: Compound Banlangen Granules converted to over-the-counter drugs
Time of Update: 2021-05-10
, 3 times a day.
>
[Adverse reactions] Monitoring data shows that this product has reports of adverse reactions such as diarrhea, abdominal pain, nausea, vomiting, abdominal discomfort, itching, rash, dizziness
-
Nursing safety is no small matter
Time of Update: 2021-05-10
for compensation for the death of the patient.
>
1. Questions about the cause of this case.
>
According to the “Regulations on Causes of Civil Cases
-
Hengrui CDK4/6 inhibitor is reported to be listed and plans to be included in priority
Time of Update: 2021-05-10
On December 24 last year, Hengrui announced that SHR6390 combined with fulvestrant in the treatment of HR-positive, HER2-negative, locally advanced or advanced breast cancer after endocrine therapy has reached the primary research endpoint.
-
Mindray's 2020 financial report: revenue of 21.026 billion and net profit increased by 42%. Research
Time of Update: 2021-05-10
026 billion yuan, a year-on-year increase of 27%; the net profit attributable to shareholders of listed companies in 2020 is approximately 6.
-
FDA issues guidelines for non-clinical research on personalized antisense oligonucleotide therapeutics
Time of Update: 2021-05-10
-threatening Diseases", introducing support for research on individualized antisense oligonucleotides Non-clinical information recommended by the FDA for the Sexual New Drug Application (IND).
>
FDA Acting
-
Howson "joined" CSPC successfully "sniped" Pfizer's sunitinib patent and was invalidated
Time of Update: 2021-05-10
-pyrrole-3-carboxamide malate crystal, its preparation method and its composition") The application date is August 13, 2002, and the authorization announcement date is December 2008 On March 3rd, the patentee was Pharmacia Upjohn Co. , Ltd
-
Major update of ASCO guidelines: Recommended initial treatment for metastatic non-castrated prostate cancer
Time of Update: 2021-05-10
In the past, ASCO has issued clinical practice guidelines for the initial hormone therapy of non-castrated
-
Express | Subcutaneous RNAi Therapy Reached All Phase 3 Clinical Endpoints, New Drug Application Has Been Submitted
Time of Update: 2021-05-10
>Hereditary transthyretin amyloidosis is a hereditary and progressive disease caused by mutations in the TTR gene. Mutations in the TTR gene cause abnormal amyloid accumulation and damage body organs
-
Kangfang Bio-PD-1/CTLA-4 Dual Antibody Approved Global Phase 3 Clinical First-line Treatment for Advanced Cervical Cancer
Time of Update: 2021-05-10
that cadonilimab has significantly reduced toxicity compared with the combination therapy of PD-1 antibody and CTLA-4 antibody, and has obvious safety and efficacy advantages.
>
Based on good clinical data, in August
-
Dialogue with Professor Yang Yong: Abiraterone helps prostate cancer patients "full process" benefit | Choose the power of "Ze
Time of Update: 2021-05-10
"Professor Yang Yong leads his "small" team to keep up with the international "trend" of prostate cancer treatment, master the experience of using new drugs and new treatment methods, and provide patients with better services.
-
FDA expert group 7:2 supports the retention of Tecentriq triple-negative breast cancer
Time of Update: 2021-05-10
In March 2019, PD-L1-positive patients' progression-free survival (PFS) results based on the IMpassion130 study of atelizumab combined with Abraxane (albumin paclitaxel) in the treatment of PD-L1-positive metastatic triple-negative breast cancer (TNBC) (7.
-
Interpretation of the Chinese Guidelines for Diabetic Nephropathy (Part 1), full of dry goods
Time of Update: 2021-05-10
Studies have shown that diabetic patients with normal proteinuria show a progressive decline in renal function after CKD3, which is why eGFR<60 ml/(min·1.
-
How to avoid severe hypoglycemia in elderly patients with type 2 diabetes who started insulin
Time of Update: 2021-05-10
Comment In this study, compared with NPH insulin, the use of long-acting insulin analogues (insulin glargine or insulin detemir) in elderly patients with type 2 diabetes is associated with a lower risk of severe hypoglycemia.
-
The 3rd Attention Deficit Hyperactivity Disorder Care Week and Adolescent Mental Health Guardian Program
Time of Update: 2021-05-10
>
On April 24, the "3rd Attention Deficit Hyperactivity Disorder (ADHD) Care Week and Adolescent Mental Health Guardian Program Kick-off Meeting" project was officially launched
-
Abdominal pain, black stools for half a month, the patient lost 10 kg...Where is the bleeding
Time of Update: 2021-05-10
This patient has a clear diagnosis of gastrointestinal bleeding, low hemoglobin, anemia, gastroscopy, colonoscopy, and capsule endoscopy for normal procedures.
-
Johnson & Johnson, AbbVie, Teva and Endo face $50 billion opioid lawsuits
Time of Update: 2021-05-10
Oklahoma believes that the aggressive marketing strategies of Johnson & Johnson and other companies have led to the proliferation of opioid prescriptions in the state.
-
Stones from Other Mountains | Experience Sharing of the Latest Approved PK Software (1): Spanish Experience
Time of Update: 2021-05-10
treatment, the complexity of traditional PK testing makes PK-guided individualized preventive treatment unable to be widely and practically applied. PK software came into being: Based on the above situation, PK tools
